PLASMA MALONDIALDEHYDE CONCENTRATION AND THE KYNURENINE/TRYPTOPHAN RATIO IN PATIENTS WITH STAGE 3–4 CHRONIC KIDNEY DISEASE AT LONG AN GENERAL HOSPITAL
Main Article Content
Abstract
Objective: To evaluate plasma malondialdehyde (MDA) concentration and the kynurenine/tryptophan (Kyn/Trp) ratio in patients with stage 3–4 chronic kidney disease (CKD), investigate the associations of these biomarkers with estimated glomerular filtration rate (eGFR), and assess the discriminative value of Kyn/Trp for identifying stage 3–4 CKD.
Subjects and Methods: This controlled cross-sectional study included 42 patients with stage 3–4 CKD and 41 healthy controls recruited from March 2025 to March 2026 at Long An General Hospital. Plasma MDA, kynurenine, and tryptophan concentrations were measured, and the Kyn/Trp ratio was calculated as the ratio of kynurenine to tryptophan concentrations. eGFR was estimated using the 2021 CKD-EPI equation.
Results: The study included 83 participants, comprising 42 patients with stage 3–4 CKD and 41 controls. Plasma MDA concentration did not differ significantly between the two groups (4.56 ± 1.52 vs. 4.83 ± 1.61 µmol/L; p = 0.43). In contrast, kynurenine concentration and the Kyn/Trp ratio were higher, whereas tryptophan concentration was lower, in patients with CKD than in controls (all p < 0.05). The Kyn/Trp ratio was higher in patients with stage 4 CKD than in those with stage 3 CKD (0.069 [0.052–0.092] vs. 0.051 [0.042–0.067]; p = 0.012). Kynurenine and Kyn/Trp were inversely correlated with eGFR (r = −0.48, p = 0.001 and r = −0.51, p < 0.001, respectively), whereas MDA was not significantly correlated with eGFR (r = −0.12, p = 0.44). Receiver operating characteristic analysis showed an area under the curve (AUC) of 0.870 for Kyn/Trp (95% CI: 0.790–0.949; p < 0.001); the model combining Kyn/Trp with hypertension had an AUC of 0.910 (95% CI: 0.836–0.984; p < 0.001).
Conclusion: The Kyn/Trp ratio was increased in patients with stage 3–4 CKD and increased with worsening kidney function, with a moderate inverse correlation with eGFR. In contrast, MDA did not differ significantly between patients with CKD and controls and was not significantly associated with eGFR.
Keywords
Chronic kidney disease, malondialdehyde, kynurenine, tryptophan, Kyn/Trp, eGFR
Article Details
References
2. Tucker PS, Dalbo VJ, Han T, Kingsley MI. Clinical and research markers of oxidative stress in chronic kidney disease. Biomarkers. 2013;18(2):103-115.
3. Schefold JC, Zeden JP, Fotopoulou C, von Haehling S, Pschowski R, Hasper D, et al. Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms. Nephrol Dial Transplant. 2009;24(6):1901-1908.
4. Tran TTX, Phan TMT, Pham TL, Nguyen THT, Phu TH. Evaluation of plasma malondialdehyde concentration and kynurenine/tryptophan ratio in patients with stage 3-4 chronic kidney disease. Tạp chí Y Dược Huế. 2024;14(6):47.
5. Mor A, Kalaska B, Pawlak D. Kynurenine Pathway in Chronic Kidney Disease: What’s Old, What’s New, and What’s Next? Int J Tryptophan Res. 2020;13:1178646920954882.
6. Pawlak D, Tankiewicz A, Mysliwiec P, Buczko W. Tryptophan metabolism via the kynurenine pathway in experimental chronic renal failure. Nephron. 2002;90(3):328-335.
7. Brekdar F, Khayat MI, Zrieki A. Plasma Kynurenine: A Promising Marker for the Assessment of Renal Functions. Int J Tryptophan Res. 2022;15:11786469221102093.
8. Liu JJ, Ching J, Wee HN, Liu S, Gurung RL, Lee J, et al. Plasma Tryptophan-Kynurenine Pathway Metabolites and Risk for Progression to End-Stage Kidney Disease in Patients With Type 2 Diabetes. Diabetes Care. 2023;46(12):2223-2231.